- Home
- FGI vs BCDA Comparison
FGI vs BCDA Comparison
Compare FGI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- BCDA
- Stock Information
- Founded
- FGI 1987
- BCDA N/A
- Country
- FGI United States
- BCDA United States
- Employees
- FGI N/A
- BCDA N/A
- Industry
- FGI Industrial Specialties
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- FGI Industrials
- BCDA Health Care
- Exchange
- FGI Nasdaq
- BCDA Nasdaq
- Market Cap
- FGI 7.7M
- BCDA 7.9M
- IPO Year
- FGI 2022
- BCDA N/A
- Fundamental
- Price
- FGI $0.91
- BCDA $2.68
- Analyst Decision
- FGI
- BCDA Strong Buy
- Analyst Count
- FGI 0
- BCDA 1
- Target Price
- FGI N/A
- BCDA $25.00
- AVG Volume (30 Days)
- FGI 8.5K
- BCDA 73.1K
- Earning Date
- FGI 11-06-2024
- BCDA 11-06-2024
- Dividend Yield
- FGI N/A
- BCDA N/A
- EPS Growth
- FGI N/A
- BCDA N/A
- EPS
- FGI 0.06
- BCDA N/A
- Revenue
- FGI $121,013,893.00
- BCDA $428,000.00
- Revenue This Year
- FGI $5.53
- BCDA $6.92
- Revenue Next Year
- FGI $5.05
- BCDA N/A
- P/E Ratio
- FGI $15.19
- BCDA N/A
- Revenue Growth
- FGI N/A
- BCDA 0.71
- 52 Week Low
- FGI $0.70
- BCDA $1.96
- 52 Week High
- FGI $1.85
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- FGI 62.84
- BCDA 49.01
- Support Level
- FGI $0.74
- BCDA $2.39
- Resistance Level
- FGI $0.99
- BCDA $2.90
- Average True Range (ATR)
- FGI 0.05
- BCDA 0.18
- MACD
- FGI 0.02
- BCDA -0.00
- Stochastic Oscillator
- FGI 71.43
- BCDA 53.70
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. It offers sanitaryware, bath furniture, shower systems, customer kitchen cabinetry, and other accessory items. It is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. its revenue is generated by sanitaryware. Geographically it operates in the United States, Canada, Europe, Rest of the World, and the majority of its revenue comes from the United States.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).